Fifty410

What Fifty410 actually is

Fifty410 is a telehealth marketplace. The company's own site is explicit about the regulatory shape: it does not compound, manufacture, or distribute medications directly. The intake form routes a buyer through a prescriber, the prescription is then filled at an independent FDA-registered 503A or 503B compounding pharmacy, and Fifty410's role is platform mechanics — intake, routing, billing, shipping logistics.

That accurate framing is itself a transparency signal. Several competing brands in this category soft-pedal the distinction or imply they are themselves the dispensing pharmacy. Fifty410 doesn't, which makes the audit work clearer: the question is which partner pharmacies Fifty410 routes to, and what the regulatory record on those partners looks like.

Why Fifty410 leads on buyer experience

Trustpilot is the most visible data point. Across roughly 4,000 reviews Fifty410 carries a 4.6–4.8 / 5 rating — the highest reading in the v0 cohort by both volume and score. The May 2026 monthly survey on r/tirzepatidecompound placed Fifty410 in the tier-2 group, behind Trillium on recommend rate but well ahead of Big Easy Weight Loss, Brello, and the second-half cohort.

The recurring positive themes in both sources are consistent: fast shipping, the named BPI partnership for the 12-week and 24-week plans, and explicit per-plan pricing so a buyer can see the unit cost on the landing page rather than mid-funnel. Recurring negatives are document-upload friction on refills and the multi-month commitment structure on the BPI plans. Neither rises to the cancellation-friction grievance pattern that drags Brello.

Who actually fills your prescription

The named partner — and the only one the company exposes publicly — is BPI Labs. The 12-week BPI plan ($499) and 24-week BPI plan ($1,099) make the pharmacy attribution explicit in the pricing tiers themselves. For those plans, the buyer knows which pharmacy is filling before they pay, which is more disclosure than Trillium offers for its mixed-pharmacy roster.

Outside the named BPI plans, Fifty410's other tiers ($133/mo program, $299/mo cash, $166/mo on the 3-month plan) do not publish the partner-pharmacy attribution. The roster beyond BPI is not visible. We treated that as an unverified blind spot rather than as a clean signal.

The FDA paper trail — what's there and what isn't

The empty fdaActions and stateBoardActions arrays in this profile's frontmatter reflect a deliberate distinction. We did not surface any FDA action against the Fifty410 entity itself, which is correct — Fifty410 isn't a pharmacy and isn't subject to FDA pharmacy-inspection authority directly. We also did not surface any FDA action against BPI Labs, the one named partner, in the public-record pass we ran for this audit. That absence is the most material difference between Fifty410's profile and Trillium's: the named partner (BPI) has a markedly cleaner public-record paper trail than Trillium's named partners (Hallandale and Seven Cells).

Important caveats on that finding:

• Absence-of-evidence is not evidence-of-absence. A clean public record at one moment can change with the next 483. The methodology page (/methodology/compounding) explains the refresh cadence we intend to run on these dossiers.
• The undisclosed partners are the blind spot. For Fifty410 plans outside the named BPI tiers, the audit cannot verify the quality of the filling pharmacy because the filling pharmacy is not named.
• PCAB and per-state license verification is still owed. This audit pass did not pull PCAB accreditation status for BPI or per-state non-resident license numbers. Both are achievable in a first-hand audit cycle.

What buyers consistently report

Outside the regulatory question, the Trustpilot review base is unusually large for this category — roughly 4,000 reviews is multiple times the volume Brello and Big Easy Weight Loss have accumulated. The 4.6–4.8 reading across that volume is durable signal, not a small-sample fluke.

Negative reviews cluster around two patterns. The first is refill friction: some buyers report being asked to re-upload identification or prescription documents on refill cycles, which adds days to delivery when timing matters. The second is plan-commitment friction: buyers who sign onto the 12-week or 24-week BPI plans have reported difficulty exiting the term mid-cycle. Neither is a quality-of-vial complaint, but both are buyer-protection drags that the rubric punishes at the priceTransparency and buyerProtection dimensions.

What's missing from public records

This audit is the public-data tier. To upgrade Fifty410 to a full audit tier we'd need:

• A first-hand consult and fill placed by the vialaudit desk, ideally on both a named-BPI plan and a non-BPI tier, to verify whether the partner-pharmacy attribution is disclosed pre-purchase on the non-BPI tiers or surfaces only on the vial label.
• The named-prescriber identity and NPI number, with state-medical-board cross-checks for the states Fifty410 ships to.
• PCAB accreditation status for BPI Labs, pulled from the PCAB directory, plus per-state non-resident license verification for BPI in the largest-population states.
• The Fifty410 written refund and cancellation policy as published, archived against any future revisions — particularly the in-term cancellation language for the 12-week and 24-week BPI plans.
• A second public-record pass on the FDA inspection database and state-board disciplinary records for BPI Labs, refreshed at the 90-day cadence the methodology page proposes.

We have not done that work yet. This profile reflects what is verifiable from public records as of the last-audited date.

Editorial note — clean paper trail vs verified clean record

Fifty410 reads as the cleanest pharmacy in the v0 cohort on the FDA-history dimension. We want to be careful about what that finding actually means. It means: the public-record pass we ran did not surface FDA actions against BPI Labs, the one named partner. It does not mean: we independently verified that BPI's sterile compounding practice meets USP <797> and <800> standards; we independently verified the partner roster beyond BPI; or we placed a fill and confirmed which pharmacy shipped it.

A buyer optimizing for the largest verifiable Trustpilot signal in the cohort and the cleanest available paper trail among named partners has reasons to choose Fifty410 that the audit supports. A buyer optimizing for full disclosure of the partner roster pre-purchase should treat the undisclosed portion of the Fifty410 partner stack as the structural gap that a first-hand audit would close.

See /methodology/compounding for the rubric weights that produce this score and the conflict-of-interest constraints that govern this desk.